drugset / Trial / NCT02451748
IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA
Non-randomizedSequentialOpen-labelBasic science
Summary
The purpose of the study is to better understand the factors present in the cells of inflamed joints of patients with arthritis that may cause rheumatoid arthritis. Knowledge gained from this study may lead to new and better therapies for arthritis.
Timeline
- Start
- 2015-08
- Primary completion
- 2017-09
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Certolizumab Pegol | Protein / enzyme biologic | 200 mg | Subcutaneous |
| Background | Adalimumab | Monoclonal antibody | 40 mg | — |
| Background | Hydroxychloroquine | Small molecule | 400 mg | — |
| Background | Leflunomide | Small molecule | 20 mg | — |
| Background | Methotrexate | Small molecule | 7.5 mg | — |
| Background | Methotrexate | Small molecule | 15 mg | — |
| Background | Methotrexate | Small molecule | 17.5 mg | — |
| Background | Methotrexate | Small molecule | 20 mg | — |
| Background | Methotrexate | Small molecule | 25 mg | — |
| Background | Methylprednisolone | Other / unclassified | 8 mg | — |
| Background | Naproxen | Small molecule | 1000 mg | — |
| Background | Prednisone | Other / unclassified | 2.5 mg | — |
| Background | Prednisone | Other / unclassified | 5 mg | — |
| Background | Prednisone | Other / unclassified | 10 mg | — |
| Background | Prednisone | Other / unclassified | 20 mg | — |
| Background | Prednisone | Other / unclassified | 30 mg | — |
| Background | Sulfasalazine | Small molecule | 300 mg | — |
| Background | Sulfasalazine | Small molecule | 1000 mg | — |
| Background | Triamcinolone | Other / unclassified | 40 mg | Intramuscular |
| Background | Triamcinolone | Other / unclassified | 80 mg | Intramuscular |